Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD

Steve W. Turner, Anne B. Chang, Ian A. Yang

    Research output: Contribution to journalReview articleResearchpeer-review

    Abstract

    Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

    Original languageEnglish
    Pages (from-to)306-316
    Number of pages11
    JournalBreathe
    Volume15
    Issue number4
    DOIs
    Publication statusPublished - 1 Dec 2019

    Fingerprint

    Chronic Obstructive Pulmonary Disease
    Nitric Oxide
    Asthma
    Eosinophilia
    Guidelines
    Biomarkers
    Research

    Cite this

    Turner, Steve W. ; Chang, Anne B. ; Yang, Ian A. / Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD. In: Breathe. 2019 ; Vol. 15, No. 4. pp. 306-316.
    @article{69ee7dd721f848209ad0c48230c83326,
    title = "Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD",
    abstract = "Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.",
    author = "Turner, {Steve W.} and Chang, {Anne B.} and Yang, {Ian A.}",
    year = "2019",
    month = "12",
    day = "1",
    doi = "10.1183/20734735.0268-2019",
    language = "English",
    volume = "15",
    pages = "306--316",
    journal = "Breathe",
    issn = "2073-4735",
    publisher = "European Respiratory Society",
    number = "4",

    }

    Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD. / Turner, Steve W.; Chang, Anne B.; Yang, Ian A.

    In: Breathe, Vol. 15, No. 4, 01.12.2019, p. 306-316.

    Research output: Contribution to journalReview articleResearchpeer-review

    TY - JOUR

    T1 - Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD

    AU - Turner, Steve W.

    AU - Chang, Anne B.

    AU - Yang, Ian A.

    PY - 2019/12/1

    Y1 - 2019/12/1

    N2 - Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

    AB - Exhaled nitric oxide fraction (FENO) values can be easily measured using portable analysers and are a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy, which is associated with elevated FENO. One guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged >5 years. The role of FENO in monitoring asthma is even less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently, FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

    UR - http://www.scopus.com/inward/record.url?scp=85075948552&partnerID=8YFLogxK

    U2 - 10.1183/20734735.0268-2019

    DO - 10.1183/20734735.0268-2019

    M3 - Review article

    VL - 15

    SP - 306

    EP - 316

    JO - Breathe

    JF - Breathe

    SN - 2073-4735

    IS - 4

    ER -